BioCentury
ARTICLE | Clinical News

Anetumab ravtansine: Phase I data

June 13, 2016 7:00 AM UTC

Data from 147 evaluable patients with advanced solid tumors refractory to standard treatment in an open-label, dose-escalation, U.S. Phase I trial showed that the maximum tolerated dose (MTD) of IV an...